This page lists past other NCI and NIH cancer imaging initiatives, including grant mechanisms.
Requests for Application (RFA) are usually announced with special application dates; there is no possibility for applying after that date. Program Announcements (PA, PAR) may be open for a set period of time, such as 3 years or less; applications submitted in response to Program Announcements may be due on the standard dates (February 1, June1, and October 1) or may have special dates for receipt of applications. Please pay attention to these dates. Contact a CIP staff member if you have questions.
Piotr Grodzinski email@example.com
Lynn Sobara, Ph.D., Tel: (301) 435-0584; Email: LynnS@mail.nih.gov
This Funding Opportunity Announcement is designed to enhance the basic and applied cancer prevention research. The National Cancer Institute (NCI) invites applications that propose small and time-limited projects pertinent to the development of cancer chemoprevention agents, biomarkers for early cancer detection, cancer-related nutrition science, and/or clinical prevention studies that focus on specific target organs. Proposed projects may involve basic and/or translational research and/or human subjects-oriented research.
Budgets for direct costs of up to $50,000 per year may be requested for a maximum of $100,000 direct costs over a 2-year (maximum time length) project period.
Among the Early Cancer Detection topics mentioned in the specific areas of research is imaging technology. The scope of the funding mechanism includes pilot or feasibility studies; secondary analyses of existing data; small, self-contained research projects; development of research methodologies; and development of new research technologies.
See full description in NIH Guide:PAR-08-055
Linda Brady, Ph.D., Tel 301-443-3563; E-mail: firstname.lastname@example.org
The purpose of the FOA, issued by the NIDA, NINDS, NIA, and NIMH, is to facilitate collaborations to extend the utility of positron emission tomography (PET) or single photon emission tomography (SPECT) radioligands in the study of brain and other organ systems to diseases beyond those for which the ligand was originally developed. An example might be the use of radioligands synthesized for probing brain systems in substance abuse for the investigation of other diseases such as cancer, schizophrenia, or obesity, or of organs other than the brain, e.g., heart, kidney, adrenal gland, ovary. Similarly, radioligands developed in a patient population afflicted with a specific disease or condition might be applied to other clinical populations with different conditions or diseases. Very often, PET or SPECT radioligands are developed at a single site with a single intended application in mind. This FOA seeks to encourage collaborations between sites that develop and use PET and/or SPECT radioligands for the purpose of expanding the range of ligand applications as well as sharing the ligands themselves or the procedures used in their development/synthesis. The overall goal of this solicitation is to optimize the utility of PET/SPECT radiotracers across organ systems and diseases and between and among sites in human subjects.
See full description in NIH Guide: RFA-DA-08-001
Jennifer Couch, Ph.D., Tel: (301) 435-5226;; Email: email@example.com
The NIH Blueprint for Neuroscience Research is a collaborative effort among the NIH Office of the Director and 15 Institutes and Centers to accelerate the pace of discovery and understanding in neuroscience research (for details see the following: http://neuroscienceblueprint.nih.gov/). This FOA is affiliated with the Neuroscience Blueprint, with Institutes and Centers participating independently, and with participation by Institutes that are not part of the Neuroscience Blueprint. The purpose of this FOA is to encourage researchers to use the caBIG™ and BIRN infrastructures to share data and tools by federating new software tools under these infrastructures or using the infrastructure to federate significant data sets. Awards issued under this FOA will NOT provide support to develop the tools or to measure data. The goal is to make these tools/data broadly available to other researchers.
See full description in NIH Guide: PAR-07-426
Suresh Mohla, Ph.D.; Phone: 301-435-1878; E-mail: firstname.lastname@example.org
This Funding Opportunity Announcement issued by the National Heart, Lung, and Blood Institute (NHLBI), in conjunction with other Institutes, solicits Research Project Grant (R01) applications from qualified researchers to investigate the biology of the lymphatic system and potential new therapeutic implications. The purpose of this program announcement is to stimulate research on the biology of the lymphatic system at all biologic levels: molecular, cellular, tissue, organ, and whole body levels. Further, it includes research on innovations for identifying and intervening in lymphatic diseases across all age groups and disease states. Examples of potential areas of research pertinent to NCI participation in PAR-07-420 are listed in the announcements. Among the examples are a) Molecular characterization and comparison of normal and tumor lymphatic endothelia and their component cells, including identifications of molecular markers, secreted factors, and/or receptors;b) Determination of the functional status of tumor lymphatic vessels, e.g. the uptake and transport of fluid and macromolecules; c)Study of the interplay between angiogenesis and lymphangiogenesis; d) Design and validation of imaging modalities to visualize normal and tumor lymphatics.
See full description in the NIH Guide: PAR-07-420
See description of NCI areas of research interest: NOT-CA-07-022
Zohara Cohen, Ph.D., Tel: 301-451-4778; E-mail: email@example.com
This FOA intends to support modification and enhancement of existing neuroimaging informatics tools and resources that are hosted or being considered for inclusion into the NIH Neuroimaging Informatics Tools and Resources Clearinghouse (NITRC, www.nitrc.org, public release scheduled for October 2007). Examples of such tools include image segmentation, image registration, image processing pipelines, statistical analysis packages, spatial alignment and normalization algorithms, and data format translators. Resources include well-characterized test datasets, data formats, and databases, among others.
See full description in NIH Guide: PAR-07-417
Anne Tatum, NCI, Phone: (301) 594-5371; E-mail: firstname.lastname@example.org
The purpose of this initiative is to stimulate multidisciplinary efforts focused on the characterization of the genetic, molecular, and/or cellular changes, and/or functional biology of pre-malignancy states of human breast cancer. The NCI solicits applications for research projects intended to facilitate the identification of those attributes of the earliest identifiable breast lesions that distinguish benign lesions from precancerous lesions. Applicants are encouraged to exploit resources and technologies that already exist, including imaging and nanotechologies. Projects taking advantage of information already available from well-validated animal model systems and quantitative modeling may also be appropriate. Two to three awards will be made.
Marjorie A. Tingle, Ph.D., NCRR, Phone: 301-435-0772; E-mail: HEI@mail.nih.gov
The NCRR High-End Instrumentation Grant (HEI) program solicits applications from groups of NIH-supported investigators to purchase a single major item of equipment to be used for biomedical research that costs at least $750,000. The maximum award is $2,000,000. Instruments in this category include, but are not limited to, structural and functional imaging systems, macromolecular NMR spectrometers, high-resolution mass spectrometers, cryoelectron microscopes and supercomputers.
Contact: Peter Lyster, Ph.D., NIGMS, Phone: 301-451-6446, Email: email@example.com
The NIH is interested in promoting research and developments in computational science and technology that will support rapid progress in areas of scientific opportunity in biomedical research. The Institutes and Centers of the NIH offer support through the current solicitation for fundamental research in biomedical information science and technology as well as for the development of new informatics, computational and mathematical tools and technologies.
See full description in NIH Guide: PAR-07-344
Contact: Anthony Hayward, Ph.D., NCRR, Phone: 301-435-0790, Email: firstname.lastname@example.org
The goal of the Institutional Clinical and Translational Science Award (CTSA) program is to transform the local, regional and national environment for clinical and translational science, thereby increasing the efficiency and speed of clinical and translational research. This transformation will be achieved by creating an academic home, which can be a center, department, or Institute (C/D/I), comprising faculty and programs that integrate clinical and translational science across multiple departments, schools, clinical and research institutes and hospitals. The C/D/I should provide clinical research resources including infrastructure and training to various disciplines in its institution (e.g., medicine, dentistry, nursing, pharmacy, public health, biostatistics, epidemiology, bioengineering) for the benefit of researchers, trainees, and research projects across multiple aspects of health promotion and disease prevention, pre-emption, and treatment studied by a wide range of NIH Institutes and Centers.
See full description in NIH Guide: RFA-RM-07-007